Effects of probiotic supplementation on exercise and the underlying mechanisms
10.3390/foods12091787 · doi-reference
Immunoregulation of synovial macrophages for the treatment of osteoarthritis
10.1515/biol-2022-0567 · doi-reference
Macrophage proliferation distinguishes 2 subgroups of knee osteoarthritis patients
10.1172/jci.insight.125325 · doi-reference
Ageing and osteoarthritis synergically affect human synoviocyte cells: an in vitro study on sex differences
10.3390/jcm11237125 · doi-reference
Mechanisms of chronic pain in osteoarthritis
10.1007/s11926-012-0279-x · doi-reference
The role of synovitis in osteoarthritis pathogenesis
10.1016/j.bone.2012.02.012 · doi-reference
Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis
10.1038/nrrheum.2016.136 · doi-reference
Targeting CD44 receptor pathways in degenerative joint diseases: involvement of proteoglycan-4
10.3390/ph16101425 · doi-reference
Neuropeptide Y and pain: insights from brain research
10.1021/acsptsci.4c00333 · doi-reference
Synovitis in osteoarthritis: current understanding with therapeutic implications
10.1186/s13075-017-1229-9 · doi-reference
The bone-cartilage unit in osteoarthritis
10.1038/nrrheum.2010.197 · doi-reference
The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolic agents
10.1136/annrheumdis-2013-204111 · doi-reference
Do neuroendocrine peptides and their receptors qualify as novel therapeutic targets in osteoarthritis?
10.3390/ijms19020367 · doi-reference
Inflammatory, structural, and pain biochemical biomarkers may reflect radiographic disc space narrowing: the Johnston county osteoarthritis project
10.1002/jor.24534 · doi-reference
Tanezumab for the treatment of osteoarthritis pain
10.1358/dot.2022.58.4.3352752 · doi-reference
Osteoarthritis
10.1002/jcp.21258 · doi-reference
Osteoarthritis: the genesis of pain
10.1093/rheumatology/kex419 · doi-reference
Neuropeptide Y and its involvement in chronic pain
10.1016/j.neuroscience.2017.08.050 · doi-reference
Zinc supplementation improved neuropeptide Y, nesfatin−1, leptin, C-reactive protein, and HOMA-IR of diet-induced obese rats
10.1007/s12011-021-02987-6 · doi-reference
Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review
10.1016/j.joca.2012.08.027 · doi-reference
Inflammatory biomarkers in osteoarthritis
10.1016/j.joca.2015.02.009 · doi-reference
Neuropeptide Y enhances proliferation and chondrogenic differentiation of ATDC5 cells
10.1016/j.npep.2020.102022 · doi-reference
Carboxypeptidase E modulates intestinal immune homeostasis and protects against experimental colitis in mice
10.1371/journal.pone.0102347 · doi-reference
Sensitization in patients with painful knee osteoarthritis
10.1016/j.pain.2010.04.003 · doi-reference
The genesis of pain in osteoarthritis: inflammation as a mediator of osteoarthritis pain
10.1016/j.cger.2021.11.013 · doi-reference
Peripheral pain mechanisms in osteoarthritis
10.1097/j.pain.0000000000001923 · doi-reference
Experimental models to study osteoarthritis pain and develop therapeutics
10.1016/j.ocarto.2022.100306 · doi-reference
Mechanisms of osteoarthritic pain. Studies in humans and experimental models
10.3389/fnmol.2017.00349 · doi-reference
A mechanism-based approach to the management of osteoarthritis pain
10.1007/s11914-015-0291-y · doi-reference
Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?
10.1097/bor.0000000000000354 · doi-reference
Tanezumab for the treatment of pain from osteoarthritis of the knee
10.1056/nejmoa0901510 · doi-reference
A stimulus-response framework to investigate the influence of continuous versus interval walking exercise on select serum biomarkers in knee osteoarthritis
10.1097/phm.0000000000001068 · doi-reference
When is osteonecrosis not osteonecrosis? Adjudication of reported serious adverse joint events in the tanezumab clinical development program
10.1002/art.39492 · doi-reference
Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial
10.1016/j.jpain.2012.05.006 · doi-reference
Recent advances in the use of stem cell-derived exosomes for joint regeneration
10.1007/s11033-026-11992-8 · doi-reference
Exosomes rewire the cartilage microenvironment in osteoarthritis: from intercellular communication to therapeutic strategies
10.1038/s41368-022-00187-z · doi-reference
Micro-fragmented adipose tissue (MFAT) in orthopedic regenerative medicine: a narrative review of the biological basis and clinical evidence
10.3390/ijms27146185 · doi-reference
A comparative study on the effect of exosomes secreted by mesenchymal stem cells derived from adipose and bone marrow tissues in the treatment of osteoarthritis-induced mouse model
10.1155/2021/9688138 · doi-reference
Neuropeptide Y-mediated gut microbiota alterations aggravate postmenopausal osteoporosis
10.1002/advs.202303015 · doi-reference
Targeting the gut microbiome to treat the osteoarthritis of obesity
10.1172/jci.insight.95997 · doi-reference
